CC BY
20
Abstracts. PHYTOPHARM 2017
INVESTIGATION OF THREE TANACETUM L. TAXA FROM TURKEY ON THE PROLIFERATION OF HUMAN PROSTATE CANCER CELLS AND EXPRESSION OF DETOXIFICATION ENZYME ACTIVITIES
© Zekiye Ceren Arituluk1, Emre Evin2, Serdar Karakurt3, Nurten Ezer1, Orhan Adah2, Ay§e Mine Gengler-Özkan4
1 Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Botany, Ankara, Turkey;
2 Middle East Technical University, Department of Biological Sciences, Joint Graduate Program in Biochemistry, Ankara, Turkey;
3 Selcuk University, Faculty of Science, Department of Biochemistry, Konya, Turkey;
4Ankara University, Faculty of Pharmacy, Department of Pharmaceutical Botany, Ankara, Turkey
The genus Tanacetum L. belonging to Asteraceae family have been used traditionally as herbal remedies in the treatment of various health problems and the members of this genus are rich in essential oils, sesquiterpenes and phenolic compounds which are responsible for their biological activities such as anti-inflammatory, cytotoxic, insecticidal [1]. Aim of this study is to investigate in vitro cytotoxic effects of methanol extracts obtained from the aerial parts of T. parthenium (L.) Schultz. Bip., T. argenteum (Lam.) Willd. subsp. canum (C.Koch) Grierson var. pumilum Grierson, and T. argenteum (Lam.) Willd. subsp. flabellifolium (Boiss. & Heldr.) Grierson on human prostate cancer cells; PC-3 (Androgen-independent) and LNCaP (Androgen-dependent) cells with Alamar Blue assay. Besides, modulatory role of those plant extracts on detoxification Phase II enzymes; glutathione-S-transferases (GST) and NAD(P)H: quinone oxidoreductase (NQO1) activities were also evaluated via spectrophotometrically.Extracts
of T. parthenium, T. argenteum subsp. canum var. pumilum and T. argenteum subsp. flabellifolium showed dose-dependent inhibition of proliferation of PC-3 cells with IC50 values of 134 |ig/mL, 72 |ig/mL, and 162 |ig/mL, respectively. Furthermore, the proliferation of LNCaP cells was also inhibited with IC50 values of 81 |ig/mL, 84 ^g/mL, and 147 ^g/mL, respectively. Interestingly, all plant extracts with IC50 value activated NQO1 enzyme activity in both PC-3 and LNCaP cells.
The results of this study have shown that methanol extracts of T. parthenium, T. argenteum subsp. canum var. pumilum andT. argenteum subsp. flabellifolium may modulate the Phase II enzymes and influence the metabolic activation of xenobiotics mediated by these enzymes.
References:
1. Gören N. et al., 2002. Stud Nat Prod Chem. 547-658.
EXPLOITING IN VITRO SYNERGISTIC INTERACTIONS BETWEEN THE CONSTITUENT PLANTS OF SOME ANTI-MALARIAL POLYHERBALS TO IMPROVE THERAPEUTIC SELECTIVITY
© Tarkang P.A.12, Appiah-Opong R.2, Ofori M.F.2, Ayong L.S.3, Nyarko A.K.24
11nstitute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon;
2 Noguchi Memorial Institute for Medical Research, Accra, Ghana;
3 Centre Pasteur du Cameroun, Yaounde, Cameroon;
4 School of Pharmacy, University of Ghana, Accra, Ghana
The low structural diversity of currently available anti-malarial drugs and the increasing ability of malaria parasites to quickly develop resistance to new anti-malarial drug molecules underscores the need to explore new therapeutic strategies. Combination therapyimproves efficacy by synergistic effects and slows down parasite resistance [1]. Hence, the potential of combiningplant extracts and/or introducing these into conventional treatment regimens are tools to be systematically explored. Our objective was to exploitin vitro synergistic interactions between the constituent
plant aqueous and ethanol extracts of six selected polyherbals (PNF, PFC, PFH, PFA, PFT, PFS), to explore strategies of improving their therapeutic selectivity.An accelerated solvent extraction (ASE) method was used to generate a 96 plants solvent extract library. In vitro antiplasmodial activities of polyherbal constituents were evaluated on multidrug resistant P. falciparum strain [2], followed by cytotoxicity screening [3]. Extract interactions were analyzed using an equipotency ratio drug combination approach [4]. The 50% fractional inhibitory concentration (FIC50) and combination indices
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy]
vol. 15/2017/suppLeMEnT 1
